SCHEDULE: Morgan Stanley Discloses 5.4% Stake in UroGen Pharma
Beneficial Ownership Disclosure
Morgan Stanley has disclosed a 5.4% beneficial ownership stake in UroGen Pharma Ltd.'s Ordinary Shares, held in the ordinary course of business.
Summary
- Morgan Stanley reported beneficial ownership of 2,488,299 Ordinary Shares of UroGen Pharma Ltd.
- This stake represents 5.4% of UroGen Pharma Ltd.'s outstanding Ordinary Shares.
- Morgan Stanley holds shared voting power over 2,463,149 shares and shared dispositive power over 2,488,299 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of a passive ownership stake. It neither indicates positive nor negative operational or financial performance, but rather a significant institutional holding.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by a major financial institution in a pharmaceutical company. It does not provide specific industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Increased transparency regarding institutional ownership and potential validation of the company by a major financial institution.
- Investment Professionals: Provides data on significant institutional holdings for portfolio analysis and market tracking.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 08/06/2025 | Date of filing signature |
Keywords
UroGen Pharma, Morgan Stanley, Beneficial Ownership, SEC Filing, Schedule 13G, Ordinary Shares, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.